PlainRecalls
FDA Drug Moderate Class II Terminated

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.

Reported: July 3, 2024 Initiated: May 13, 2024 #D-0568-2024

Product Description

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.

Reason for Recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Details

Units Affected
21,655 (30 count bottle), 34,149 (90 count bottle)
Distribution
Nationwide in the U.S.
Location
Camarillo, CA

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.. Recalled by Golden State Medical Supply Inc.. Units affected: 21,655 (30 count bottle), 34,149 (90 count bottle).
Why was this product recalled?
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 3, 2024. Severity: Moderate. Recall number: D-0568-2024.